AROAF (Aroa Biosurgery) Shares Outstanding (EOP): 345.48 Mil (As of Mar. 2026)


AROAF Aroa Biosurgery Ltd AROAF
39 GF Score
Price $0.52
GF Value $0.71
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery Shares Outstanding (EOP)?

Aroa Biosurgery AROAF +35.24% 39 Shares Outstanding (EOP) is 345.48 Mil as of Mar. 2026. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Aroa Biosurgery's shares outstanding for the quarter that ended in Mar. 2026 was 345.48 Mil.

Aroa Biosurgery's quarterly shares outstanding increased from Sep. 2025 (345.03 Mil) to Mar. 2026 (345.48 Mil). It means Aroa Biosurgery issued new shares from Sep. 2025 to Mar. 2026 .

Aroa Biosurgery's annual shares outstanding increased from Mar. 2025 (344.90 Mil) to Mar. 2026 (345.48 Mil). It means Aroa Biosurgery issued new shares from Mar. 2025 to Mar. 2026 .


Aroa Biosurgery  (OTCPK:AROAF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Aroa Biosurgery Shares Outstanding (EOP) Related Terms


Aroa Biosurgery Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Shares Outstanding (EOP) Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shares Outstanding (EOP)
Get a 7-Day Free Trial 342.46 343.11 344.21 344.90 345.48

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 344.21 344.90 344.90 345.03 345.48

AROAF vs ABT, SYK, MDT: Shares Outstanding (EOP) Comparison

For the Medical Devices subindustry, Aroa Biosurgery's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aroa Biosurgery Shares Outstanding (EOP) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's Shares Outstanding (EOP) falls into.


AROAF
39GF Score
Aroa Biosurgery Ltd AROAF
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 345.48 Mil mean?
Aroa Biosurgery (AROAF) has a Shares Outstanding (EOP) of 345.48 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Shares Outstanding (EOP) too high?
Aroa Biosurgery's current Shares Outstanding (EOP) is 345.48 Mil. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Shares Outstanding (EOP) compare to ABT and SYK?
Aroa Biosurgery's Shares Outstanding (EOP) of 345.48 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Devices & Instruments company?
A good Shares Outstanding (EOP) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current Shares Outstanding (EOP) is 345.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current Shares Outstanding (EOP) is 345.48 Mil. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current Shares Outstanding (EOP) is 345.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (AROAF) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for AROAF:

  • Shares Outstanding (EOP): 345.48 Mil
  • GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
  • GF Score™: 39/100 with 1 warning sign

No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aroa Biosurgery Business Description

Other Exchanges ARX:Australia
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
39GF Score

Get the complete analysis for AROAF

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price
$0.71
GF Value